Inclusion Criteria:

- Histologic or cytologic diagnosis of breast cancer Stage IV or recurrent.

- Previous chemotherapy with anthracyclines and taxane in adjuvant setting

- Previous hormonal therapy in adjuvant and metastatic setting is allowed

- Prior radiation therapy is allowed as long as the irradiated area is not the only
source of measurable disease.

- No other forms of cancer therapy, such as radiation, immunotherapy for at least 3
weeks before the enrollment in study.

- Performance status of 0, 1, 2 on the ECOG criteria.

- Clinically measurable disease, defined as uni-dimensionally measurable lesions with
clearly defined margins on x-ray, CT scan, MRI or physical examination. Lesions
serving as measurable disease must be at least 1 cm, as defined by x-ray, CT scan,
MRI, or physical examination.

- Estimated life expectancy of at least 12 weeks.

- Patient compliance that allow adequate follow-up.

- Adequate hematologic (WBC count ³ 3,000/mm3, platelet count ³ 100,000/mm3), hepatic
(bilirubin level £ 1.5 mg/dL), and renal (creatinine concentration £ 1.5 mg/dL)
function.

- Informed consent from patient or patient's relative.

- Males or females at least 18 years of age.

- If female: childbearing women should use non-hormonal contraceptive method

Exclusion Criteria:

- MI within preceding 6 months or symptomatic heart disease, including unstable angina,
congestive heart failure or uncontrolled arrhythmia.

- Serious concomitant infection.

- Second primary malignancy (except in situ carcinoma of the cervix or adequately
treated basal cell carcinoma of the skin or prior malignancy treated more than 5
years ago without recurrence).